Although ATM mutations in CRC have shown promising results with PARPi, there is no universally accepted biomarker to reliably predict response to PARP inhibitors in colon cancer, which can lead to suboptimal patient selection and treatment outcomes [94]. This evidence concerns the gene PARP1 and malignant colon neoplasm.